Siddhartha Mukherjee (Photo by Brian Ach/Getty Images for The New Yorker)

Mukher­jee and Vale's Myeloid teams up with David Li­u's Prime Med­i­cine in race against Tessera

Sid­dhartha Mukher­jee and Ronald Vale’s Myeloid Ther­a­peu­tics think it’s got the win­ning IP for RNA-based gene-in­ser­tion tech­nol­o­gy, and the biotech is team­ing up with David Liu’s Prime Med­i­cine to take it mul­ti­tudes fur­ther than it could have done so­lo.

“There’s on­ly re­al­ly one oth­er com­pa­ny work­ing in this space that we know of, and that’s Tessera,” Myeloid CEO Daniel Getts told End­points News. Tessera has the back­ing of Mod­er­na in­cu­ba­tor Flag­ship Pi­o­neer­ing.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.